Publication | Open Access

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Multicohort StudyCheckmate 012MedicinePharmacologyImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyPhase 1Lung Cancer